Leerink Partners Reiterates Buy Rating on AbbVie

Summary

Leerink Partners reiterated a Buy rating on AbbVie (NYSE: ABBV) on September 24, despite mixed ratings from other analysts and recent insider selling activity.Tip Ranks

Impact Analysis

So basically, Leerink Partners is doubling down on AbbVie, reiterating their Buy rating despite some mixed signals from other analysts and insider selling. This move suggests Leerink sees strong underlying fundamentals or upcoming catalysts that could drive AbbVie’s stock higher. The interesting part isn’t just the Buy rating—it’s the timing. With AbbVie recently hitting a 52-week high and other analysts raising price targets, Leerink’s reiteration might be a signal of confidence in AbbVie’s strategic positioning post-Humira patent expiry, especially with new products like Skyrizi and Rinvoq gaining traction.Market Beat+ 2 Market’s missing that despite the EPS miss, revenue growth is solid, and institutional investors are increasing their stakes.Market Beat+ 2 I’d read this as a potential opportunity to capitalize on AbbVie’s growth trajectory, but keep an eye on insider sales as a potential risk factor.